Wockhardt reports flat Q1 results, advances antibiotic pipeline
Wockhardt reported Q1 FY26 revenue of INR 738 crore, down slightly from INR 747 crore previously, while EBITDA rose marginally to INR 101 crore from INR 100 crore. The company strategically exited its US generics business to focus on innovation-led growth.
Key pipeline progress included filing ZAYNICH for approval in India and completing pre-NDA meetings with the US FDA. MIQNAF NAFITHROMYCIN was approved and launched in India on May 27, 2025.
Wockhardt filed 5 new patents and received 5 patent grants during the quarter, bringing total patents held to 853.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Wockhardt publishes news
Free account required • Unsubscribe anytime